Ibuprofen and Glutathione Conjugate as a Potential Therapeutic Agent for Treating Alzheimer's Disease
- 22 December 2010
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 344 (3) , 139-148
Abstract
Non‐steroidal anti‐inflammatory drugs (NSAIDs) and antioxidant therapy might protect against the development of Alzheimer's disease (AD). In the present work, we synthesized a molecular combination of glutathione (GSH) and ibuprofen (IBU) via an amide bond and investigated its potential for targeted delivery of the parent drugs to neurons, where cellular oxidative stress and inflammation are related to AD. Evaluation of its physicochemical and in‐vitro antioxidant properties indicated that compound 1 exhibits good stability toward human plasma enzymatic activity, and, like GSH, displays in‐vitro free radical scavenging activity in a time and concentration‐dependent manner. The new compound was also assessed by infusion in a rat model for Alzheimer's disease for its potential to antagonize the deleterious structural and cognitive effects of β‐amyloid(1‐40). In behavioral tests of long‐term spatial memory, animals treated with codrug 1 performed significantly better than those treated with β‐amyloid (Aβ) peptide. Histochemical findings confirmed the behavioral data, revealing that Aβ protein was less expressed in cerebral cortex treated with 1 than that treated with IBU. Taken together, the present findings suggest that conjugate 1 treatment may protect against the oxidative stress generated by reactive oxygen species (ROS) and the cognitive dysfunction induced by intracerebroventricular (i.c.v.) infusion of Aβ(1‐40) in rats, and thus that codrug 1 could prove useful as a tool for controlling AD induced cerebral amyloid deposits and behavioral deterioration.Keywords
This publication has 40 references indexed in Scilit:
- Codrugs Linking l-Dopa and Sulfur-Containing Antioxidants: New Pharmacological Tools against Parkinson’s DiseaseJournal of Medicinal Chemistry, 2008
- Synthesis and free radical scavenging activity of some new spiropyranocoumarinsBioorganic & Medicinal Chemistry Letters, 2008
- α-Lipoic acid in dietary supplements: Development and comparison of HPLC-CEAD and HPLC-ESI-MS methodsJournal of Pharmaceutical and Biomedical Analysis, 2007
- Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitroNeuropharmacology, 2005
- One‐compound‐multiple‐targets strategy to combat Alzheimer's diseaseFEBS Letters, 2005
- Gender differences in glutathione metabolism in Alzheimer's diseaseJournal of Neuroscience Research, 2005
- Determination of formaldehyde in spirits by high-performance liquid chromatography with diode-array detection after derivatizationAnalytica Chimica Acta, 2004
- NSAID and Alzheimer's disease; possible answers and new questionsMolecular Psychiatry, 2002
- Elevated glutathione as a therapeutic strategy in Alzheimer's diseaseDrug Development Research, 2002
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995